Axicabtagene ciloleucel Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Axicabtagene ciloleucel Growth

1. Expansion into earlier-line large B-cell lymphoma treatment:

A major commercial driver is YESCARTA's use in the second-line setting for adults with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months. The ZUMA-7 Phase III trial demonstrated substantially better outcomes versus standard second-line therapy: median event-free survival was 8.3 months vs. 2.0 months, while response rates were 83% vs. 50% and complete response rates were 65% vs. 32%. Longer follow-up subsequently demonstrated significantly longer overall survival with axi-cel. This earlier-line positioning gives YESCARTA access to a larger treatment opportunity than a therapy restricted to heavily pretreated patients.

2. Strong and durable efficacy in relapsed/refractory follicular lymphoma:

YESCARTA is also approved for adults with relapsed/refractory follicular lymphoma after >=2 systemic therapies. Long-term ZUMA-5 data provide an important foundation for continued adoption: at a median follow-up of 64.6 months, axi-cel produced a 90% overall response rate and 75% complete response rate, with median duration of response of 60.4 months and median PFS of 62.2 months across the evaluated indolent NHL population. Importantly, 55% of patients were alive without requiring subsequent anticancer therapy at data cutoff. Such durability supports the positioning of axi-cel as a potentially long-lasting treatment option in heavily pretreated FL.

3. Broader addressable patient population from multiple approved lymphoma settings:

The current FDA labeling covers several clinically important populations, including first-line-refractory/early-relapsed large B-cell lymphoma, >=2-line relapsed/refractory large B-cell lymphoma, and >=2-line relapsed/refractory follicular lymphoma. The LBCL label includes DLBCL, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma. This multi-indication positioning allows YESCARTA to serve different segments of the aggressive and indolent B-cell lymphoma market rather than relying on a single indication.

4. Improving treatment accessibility following FDA elimination of CAR-T REMS:

In 2025, the FDA eliminated the REMS requirements for autologous CAR-T therapies including YESCARTA. The change removed the requirement for specially certified hospitals and associated clinics to maintain immediate on-site access to tocilizumab under the former REMS framework, while labeling was updated to streamline monitoring requirements. Reducing administrative and institutional burdens can facilitate broader availability of CAR-T treatment and potentially support utilization at additional treatment centers.

5. Growing clinical evidence supporting long-term disease control:

Continued publication of long-term clinical data can strengthen physician confidence in axi-cel. In ZUMA-5, the five-year analysis found that progression or lymphoma-related deaths became uncommon after approximately 30 months, while late-onset toxicities were infrequent. Similarly, ZUMA-7 demonstrated durable benefit in the second-line LBCL population. These data are particularly relevant for CAR-T because the possibility of prolonged treatment-free remission differentiates cellular therapy from repeated cycles of conventional systemic treatment.

Axicabtagene ciloleucel Recent Developments

In February 2026, Kite, a Gilead Company announced the US Food and Drug Administration (FDA) approved an update to the YESCARTA (axicabtagene ciloleucel) prescribing information removing the previous Limitations of Use in patients with relapsed or refractory (R/R) primary central nervous system lymphoma (PCNSL). The updated label reinforces the robust safety data of YESCARTA in eligible patients with R/R PCNSL; YESCARTA is the only CAR T-cell therapy approved for R/R large B-cell lymphoma to have this Limitations of Use removed.

"Axicabtagene ciloleucel Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Axicabtagene ciloleucel for approved indication like B-cell lymphoma, Diffuse large B cell lymphoma, and Follicular lymphoma; as well as potential indication like Haematological malignancies, Solid tumours, Marginal zone B-cell lymphoma, and Non-Hodgkin's lymphoma in the 7MM. A detailed picture of Axicabtagene ciloleucel's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Axicabtagene ciloleucel for approved and potential indications. The Axicabtagene ciloleucel market report provides insights about Axicabtagene ciloleucel's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Axicabtagene ciloleucel performance, future market assessments inclusive of the Axicabtagene ciloleucel market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Axicabtagene ciloleucel sales forecasts, along with factors driving its market.

Axicabtagene ciloleucel Drug Summary

Axicabtagene ciloleucel (YESCARTA) is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Kite Pharma, a Gilead Sciences company, for the treatment of certain B-cell malignancies. It is a genetically modified cellular immunotherapy designed to target CD19, a protein expressed on the surface of malignant and normal B cells. The therapy is manufactured by collecting the patient's own T cells through leukapheresis, genetically engineering them to express a CD19-directed CAR, expanding the modified cells, and reinfusing them into the patient following lymphodepleting chemotherapy. After administration, the engineered T cells recognize and bind to CD19-expressing cancer cells, triggering T-cell activation, proliferation, and targeted tumor-cell destruction. Axicabtagene ciloleucel is administered as a single intravenous infusion and is approved for several indications, including adult patients with relapsed or refractory large B-cell lymphomas, such as diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma transformed from indolent disease, as well as adult patients with relapsed or refractory follicular lymphoma after multiple lines of systemic therapy, depending on the applicable regulatory approval. Its clinical value is supported by durable responses observed in certain patients with aggressive B-cell lymphomas; however, treatment requires specialized centers and monitoring due to potentially serious adverse events, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), prolonged cytopenias, infections, and B-cell aplasia. Axicabtagene ciloleucel represents an important advancement in personalized cancer treatment by utilizing the patient's own immune cells to deliver targeted antitumor activity in hematologic malignancies. The report provides Axicabtagene ciloleucel's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Axicabtagene ciloleucel Market Report

The report provides insights into:

• A comprehensive product overview including the Axicabtagene ciloleucel MoA, description, dosage and administration, research and development activities in approved indications like B-cell lymphoma, Diffuse large B cell lymphoma, and Follicular lymphoma; as well as potential indication like Haematological malignancies, Solid tumours, Marginal zone B-cell lymphoma, and Non-Hodgkin's lymphoma.
• Elaborated details on Axicabtagene ciloleucel regulatory milestones and other development activities have been provided in Axicabtagene ciloleucel market report.
• The report also highlights Axicabtagene ciloleucel's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Axicabtagene ciloleucel market report also covers the patents information, generic entry and impact on cost cut.
• The Axicabtagene ciloleucel market report contains current and forecasted Axicabtagene ciloleucel sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Axicabtagene ciloleucel market report also features the SWOT analysis with analyst views for Axicabtagene ciloleucel in approved and potential indications.

Methodology:

The Axicabtagene ciloleucel market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Axicabtagene ciloleucel Analytical Perspective by DelveInsight

• In-depth Axicabtagene ciloleucel Market Assessment

This Axicabtagene ciloleucel sales market forecast report provides a detailed market assessment of Axicabtagene ciloleucel for approved indication like B-cell lymphoma, Diffuse large B cell lymphoma, and Follicular lymphoma; as well as potential indication like Haematological malignancies, Solid tumours, Marginal zone B-cell lymphoma, and Non-Hodgkin's lymphoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Axicabtagene ciloleucel sales data uptil 2034.

• Axicabtagene ciloleucel Clinical Assessment

The Axicabtagene ciloleucel market report provides the clinical trials information of Axicabtagene ciloleucel for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Axicabtagene ciloleucel Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Axicabtagene ciloleucel Market Potential & Revenue Forecast

• Projected market size for the Axicabtagene ciloleucel and its key indications
• Estimated Axicabtagene ciloleucel sales potential (Axicabtagene ciloleucel peak sales forecasts)
• Axicabtagene ciloleucel Pricing strategies and reimbursement landscape

Axicabtagene ciloleucel Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Axicabtagene ciloleucel Market positioning compared to existing treatments
• Axicabtagene ciloleucel Strengths & weaknesses relative to competitors

Axicabtagene ciloleucel Regulatory & Commercial Milestones

• Axicabtagene ciloleucel Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Axicabtagene ciloleucel Clinical Differentiation

• Axicabtagene ciloleucel Efficacy & safety advantages over existing drugs
• Axicabtagene ciloleucel Unique selling points

Axicabtagene ciloleucel Market Report Highlights

• In the coming years, the Axicabtagene ciloleucel market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Axicabtagene ciloleucel companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Axicabtagene ciloleucel's dominance.
• Other emerging products for B-cell lymphoma, Diffuse large B cell lymphoma, and Follicular lymphoma; as well as potential indication like Haematological malignancies, Solid tumours, Marginal zone B-cell lymphoma, and Non-Hodgkin's lymphoma are expected to give tough market competition to Axicabtagene ciloleucel and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Axicabtagene ciloleucel in approved and potential indications.
• Analyse Axicabtagene ciloleucel cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Axicabtagene ciloleucel sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Axicabtagene ciloleucel in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Axicabtagene ciloleucel? How strong is Axicabtagene ciloleucel's clinical and commercial performance?
• What is Axicabtagene ciloleucel's clinical trial status in each individual indications such as B-cell lymphoma, Diffuse large B cell lymphoma, and Follicular lymphoma; as well as potential indication like Haematological malignancies, Solid tumours, Marginal zone B-cell lymphoma, and Non-Hodgkin's lymphoma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Axicabtagene ciloleucel Manufacturers?
• What are the key designations that have been granted to Axicabtagene ciloleucel for approved and potential indications? How are they going to impact Axicabtagene ciloleucel's penetration in various geographies?
• What is the current and forecasted Axicabtagene ciloleucel market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Axicabtagene ciloleucel in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Axicabtagene ciloleucel for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Axicabtagene ciloleucel? What is the duration of therapy and what are the geographical variations in cost per patient?